Effect of sodium hyaluronate eyedrop on contact lens wettability

CooperVision Inc. (USA)0 个研究点目标入组 20 人2017年11月30日

概览

暂无简介。

注册库

who.int

开始日期

2017年11月30日

结束日期

2018年1月31日

最后更新

8年前

研究类型

Interventional

性别

All

发起方

CooperVision Inc. (USA)

•1\. At least 18 years old
•2\. Have read and understood the Participant Information Sheet
•3\. Have read, signed and dated the Informed Consent
•4\. Current symptomatic daily disposable contact lens wearer
•5\. Spectacle refraction: distance sphere: \-6\.00D to \+ 4\.00D; Astigmatism: 0\.00D to \-0\.75D
•6\. Best corrected visual acuity of at least 20/30 in each eye
•7\. Have normal eyes with the exception of the need for visual correction
•8\. Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule

•1\. Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear
•2\. Use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator
•3\. Monocular participants (only one eye with functional vision) or participants fit with only one contact lens
•4\. Any moderate or severe ocular condition observed during the slit\-lamp examination at the enrolment visit
•5\. History of herpetic keratitis, ocular surgery or irregular cornea
•6\. Known pregnancy or lactation during the study period
•7\. Enrollment of the investigator or his/her staff, family members of the investigator, family members of the investigator’s staff, or individuals living in the households of these individuals
•8\. Participation in any clinical trial within 30 days of the enrolment visit